Search This Blog

Friday, November 22, 2019

Aquestive +14% after FDA approves Exservan ALS film

Aquestive Therapeutics (NASDAQ:AQST) is up 14.3% after hours following FDA approval for Exservan, its riluzole oral film for patients with ALS.
The Pdufa date was Nov. 30.
The product’s recommended dosage is 50 mg twice daily.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)